Home \ Ophthalmology \ Glaucoma and Age-Related Macular Degeneration in Clinical Practice

Glaucoma and age -related macular degeneration in clinical practice

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:00
About glaucoma and its interdisciplinary nature
03:00
Embryogenesis and the structure of the visual analyzer, pathogenesis of glaucoma
04:00
Signs by which the doctor can suspect the development of glaucoma
06:23
Expanding the possibilities of drug treatment of glaucoma
09:49
The role of neurocytoprotectors in the treatment of glaucoma
14:59
The effectiveness of the drug Mexidol® in the treatment of glaucoma - research
19:00
The positive effect of antioxidant Mexidol® on visual functions in patients with glaucoma

Evgeniya Viktorovna Yekusheva – Doctor of Medical Sciences, Professor, Head of the Department of Nervous System Diseases and Neurorehabilitation of the Academy of Postgraduate Education of the Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of Russia

Egorov Evgeniy Alekseevich – Doctor of Medical Sciences, Professor, President of the Russian Glaucoma Society, Head. Department of Ophthalmology named after. Academician A.P. Nesterov RNRMU named after. N.I. Pirogov

Announcement:

Glaucoma is a disease characterized by increased intraocular pressure. This leads to damage to the optic nerve and vision loss. However, don't despair! Early diagnosis, appropriate treatment, and the use of neurocytoprotectors can prevent vision loss. The role of hypoxia, chemical imbalances, and oxidative stress in the pathogenesis of glaucoma is undeniable. But what role do neurocytoprotectors play in patients with glaucoma? Research shows that neurocytoprotectors play a crucial role in maintaining visual function in patients with this disease. They help maintain the survival of retinal ganglion cells and slow optic nerve degeneration. Mexidol® is one proven neurocytoprotector. Studies of Mexidol® confirm its high efficacy in the treatment of glaucoma and other optic nerve diseases.

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:00
About glaucoma and its interdisciplinary nature
03:00
Embryogenesis and the structure of the visual analyzer, pathogenesis of glaucoma
04:00
Signs by which the doctor can suspect the development of glaucoma
06:23
Expanding the possibilities of drug treatment of glaucoma
09:49
The role of neurocytoprotectors in the treatment of glaucoma
14:59
The effectiveness of the drug Mexidol® in the treatment of glaucoma - research
19:00
The positive effect of antioxidant Mexidol® on visual functions in patients with glaucoma

Block of articles on this topic

The effect of antioxidant therapy on some pathogenetic factors of primary open -angle glaucoma

Authors:
T.N. MALISHEVSKAYA¹, Yu.E. FILIPPOVA²

¹Federal State Budgetary Institution "Helmholtz National Medical Research Center for Eye Diseases" of the Ministry of Health of the Russian Federation, Moscow, Russia;
²State Autonomous Healthcare Institution of the Tyumen Region "Regional Ophthalmological Dispensary", Tyumen, Russia

Mexidol in the complex treatment of glaucoma

Author:
E.A. EGOROV, N.G. DAVYDOVA, I.A. ROMANENKO, N.D. NOVIKOVA

RNIMU named after N.I. Pirogov, GB of GB named after Helmholtz, Moscow

The possibilities and results of the use of antioxidant therapy in ophthalmological practice

Authors:
A.B. MOVSISYAN^1,2, Zh.G. OGANEZOVA^2,3, E.A. EGOROV²

¹Hospital for War Veterans No. 2 of the Moscow Health Department, Moscow, Russia;
²Pirogov Russian National Research Medical University, Moscow, Russia;
³Bochkov Medical Genetic Research Center, Moscow, Russia

The experience of neuroprotective therapy of primary open -angle glaucoma based on the use of various forms of Mexidol

Authors:
E.S. LEONOVA^1,2, S.V. POLYAKOV^1,2, M.A. POZDNYAKOVA², E.P. YARYGINA³, S.O. SEMISYNOV²

^1.NGO "Road Clinical Hospital at Gorky Station of JSC "Russian Railways", Inter-Road Ophthalmology Center
^2.State Budgetary Educational Institution of Higher Professional Education "Nizhny Novgorod State Medical Academy"
^3.State Budgetary Healthcare Institution of the Nizhny Novgorod Region "City Hospital No. 35", City Glaucoma Center

The use of Mexidol in the treatment of primary open -angle glaucoma

Authors:
I.A. LOSKUTOV, O.M. ANDRYUKHINA, A.A. KOVRIZHKINA

Moscow Regional Research Clinical Institute. M.F. Vladimir

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com